These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37052045)

  • 1. Prolonged Exercise With an Open-Source Automated Insulin Delivery System: Data of the Exercise Camp 2022 Austria.
    Müller-Korbsch M; Kietaibl AT; Frühwald L; Heer M; Fasching P
    J Diabetes Sci Technol; 2023 May; 17(3):857-859. PubMed ID: 37052045
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of the CamAPS FX hybrid closed-loop insulin delivery system on sleep traits in older adults with type 1 diabetes.
    Thabit H; Boughton C; Mubita W; Rubio J; Mader JK; Narendran P; Evans M; Leelarathna L; Wilinska ME; Fullwood C; Gregory AM; Hovorka R; Rutter MK
    Diabetes Obes Metab; 2023 Mar; 25(3):889-893. PubMed ID: 36335565
    [No Abstract]   [Full Text] [Related]  

  • 3. Are nocturnal hypoglycemia prevention strategies influenced by diabetes technology usage? A BETTER registry analysis.
    Talbo MK; Rabasa-Lhoret R; Yale JF; Peters TM; Brazeau AS
    Diabetes Res Clin Pract; 2022 Sep; 191():110080. PubMed ID: 36099973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of hybrid closed-loop insulin delivery on cardiac rhythm in older adults with type 1 diabetes: A post hoc analysis of trial data.
    Thabit H; Boughton C; Mubita W; Rubio J; Allen S; Heugh R; Mader JK; Narendran P; Evans M; Leelarathna L; Wilinska ME; Fullwood C; Garratt C; Hovorka R; Rutter MK
    Diabetes Obes Metab; 2024 Mar; 26(3):1105-1109. PubMed ID: 37984425
    [No Abstract]   [Full Text] [Related]  

  • 5. Exercising Safely with the MiniMed™ 780G Automated Insulin Delivery System.
    O'Neal DN; Zaharieva DP; Morrison D; McCarthy O; Nørgaard K
    Diabetes Technol Ther; 2024 Mar; 26(S3):84-96. PubMed ID: 38377316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the technical reliability and insulin dosing of a "do-it-yourself artificial pancreas" with a commercial hybrid closed-loop system in a "shadow-mode" scenario: An exploratory study.
    Künzler J; Züger T; Stettler C; Laimer MW; Melmer A
    Diabetes Obes Metab; 2023 Sep; 25(9):2780-2783. PubMed ID: 37311723
    [No Abstract]   [Full Text] [Related]  

  • 7. Extended Use of an Open-Source Automated Insulin Delivery System in Children and Adults with Type 1 Diabetes: The 24-Week Continuation Phase Following the CREATE Randomized Controlled Trial.
    Burnside MJ; Lewis DM; Crocket HR; Meier RA; Williman JA; Sanders OJ; Jefferies CA; Faherty AM; Paul RG; Lever CS; Price SKJ; Frewen CM; Jones SD; Gunn TC; Lampey C; Wheeler BJ; de Bock MI
    Diabetes Technol Ther; 2023 Apr; 25(4):250-259. PubMed ID: 36763345
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of faster-acting aspart with insulin aspart under conditions mimicking underestimation or missed meal boluses in type 1 diabetes using closed-loop insulin delivery.
    Thabit H; Mubita W; Rubio J; Karuppan M; Schofield J; Willinska ME; Hovorka R; Leelarathna L
    Diabetes Obes Metab; 2023 Apr; 25(4):1121-1124. PubMed ID: 36514847
    [No Abstract]   [Full Text] [Related]  

  • 9. Variability of Insulin Requirements in Adults with Type 2 Diabetes During Fully Closed-Loop Insulin Delivery.
    Lakshman R; Daly AB; Nwokolo M; Hartnell S; Wilinska ME; Cezar A; Evans ML; Hovorka R; Boughton CK
    Diabetes Technol Ther; 2023 Jun; 25(6):442-444. PubMed ID: 36971607
    [No Abstract]   [Full Text] [Related]  

  • 10. Insulin Requirements Over Eight Weeks of Fully Closed-Loop Insulin Delivery in Adults With Type 2 Diabetes.
    Lakshman R; Daly AB; Nwokolo M; Hartnell S; Wilinska ME; Cezar A; Evans ML; Hovorka R; Boughton CK
    J Diabetes Sci Technol; 2023 May; 17(3):868-870. PubMed ID: 36912020
    [No Abstract]   [Full Text] [Related]  

  • 11. Outpatient Randomized Crossover Automated Insulin Delivery Versus Conventional Therapy with Induced Stress Challenges.
    Kaur RJ; Deshpande S; Pinsker JE; Gilliam WP; McCrady-Spitzer S; Zaniletti I; Desjardins D; Church MM; Doyle Iii FJ; Kremers WK; Dassau E; Kudva YC
    Diabetes Technol Ther; 2022 May; 24(5):338-349. PubMed ID: 35049354
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of Type 1 Diabetes Mellitus Using Open-Source Automated Insulin Delivery During Pregnancy: A Case Series.
    Schütz AK; Schütz-Fuhrmann I; Stadler M; Staudinger H; Mader JK
    Diabetes Technol Ther; 2022 Mar; 24(3):227-230. PubMed ID: 34542371
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment of the "Second Day" Exercise Effect on Glycemic Control, Insulin Requirements, and CHO Intake in Type 1 Diabetes Adults.
    Müller-Korbsch M; Frühwald L; Heer M; Fangmeyer-Binder M; Reinhart-Mikocki D; Fasching P
    J Diabetes Sci Technol; 2021 Jan; 15(1):127-133. PubMed ID: 31583900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Health Economics of Automated Insulin Delivery Systems and the Potential Use of Time in Range in Diabetes Modeling: A Narrative Review.
    Mathieu C; Ahmed W; Gillard P; Cohen O; Vigersky R; de Portu S; Ozdemir Saltik AZ
    Diabetes Technol Ther; 2024 Mar; 26(S3):66-75. PubMed ID: 38377319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System.
    Polonsky WH; Hood KK; Levy CJ; MacLeish SA; Hirsch IB; Brown SA; Bode BW; Carlson AL; Shah VN; Weinstock RS; Bhargava A; Jones TC; Aleppo G; Mehta SN; Laffel LM; Forlenza GP; Sherr JL; Huyett LM; Vienneau TE; Ly TT;
    Diabetes Res Clin Pract; 2022 Aug; 190():109998. PubMed ID: 35853530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Future of Automated Insulin Delivery (AID) Systems.
    Garg SK; McVean JJ
    Diabetes Technol Ther; 2024 Mar; 26(S3):1-6. PubMed ID: 38377322
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy.
    Davis GM; Peters AL; Bode BW; Carlson AL; Dumais B; Vienneau TE; Huyett LM; Ly TT
    Diabetes Care; 2023 Apr; 46(4):742-750. PubMed ID: 36787903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics.
    Henry Z; Villar Fimbel S; Bendelac N; Perge K; Thivolet C
    Diabetes Obes Metab; 2024 Feb; 26(2):557-566. PubMed ID: 37905353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time In Range in Children with Type 1 Diabetes Using Treatment Strategies Based on Nonautomated Insulin Delivery Systems in the Real World.
    Cherubini V; Bonfanti R; Casertano A; De Nitto E; Iannilli A; Lombardo F; Maltoni G; Marigliano M; Bassi M; Minuto N; Mozzillo E; Rabbone I; Rapini N; Rigamonti A; Salzano G; Scaramuzza A; Schiaffini R; Tinti D; Toni S; Zagaroli L; Zucchini S; Maffeis C; Gesuita R
    Diabetes Technol Ther; 2020 Jul; 22(7):509-515. PubMed ID: 32073311
    [No Abstract]   [Full Text] [Related]  

  • 20. Automated Insulin Delivery Around Exercise in Adults with Type 1 Diabetes: A Pilot Randomized Controlled Study.
    McCarthy OM; Christensen MB; Kristensen KB; Schmidt S; Ranjan AG; Bain SC; Bracken RM; Nørgaard K
    Diabetes Technol Ther; 2023 Jul; 25(7):476-484. PubMed ID: 37053529
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.